Inosine
Product Code: AG-CR1-3554
Product Group: Natural Products and Extracts
Supplier: AdipoGen Life Sciences
| Code | Size | Price |
|---|
| AG-CR1-3554-M100 | 100 mg | £30.00 |
Quantity:
| AG-CR1-3554-M500 | 500 mg | £45.00 |
Quantity:
| AG-CR1-3554-G001 | 1 g | £65.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
Short term: +20°C, Long term: +4°C.
Documents
Further Information
Alternate Names/Synonyms:
9-beta-D-Ribofuranosylhypoxanthine; NSC 20262; Hypoxanthine 9-beta-D-ribofuranoside
Appearance:
White to off-white solid.
CAS:
58-63-9
EClass:
32160000
Form (Short):
solid
InChi:
InChI=1S/C10H12N4O5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18/h2-4,6-7,10,15-17H,1H2,(H,11,12,18)/t4-,6-,7-,10-/m1/s1
InChiKey:
UGQMRVRMYYASKQ-KQYNXXCUSA-N
Long Description:
Chemical. CAS: 58-63-9. Formula: C10H12N4O5. MW: 268.2. Inosine, an intermediate in purine metabolism, consists of hypoxanthine and ribose. It is an inert purine nucleoside formed by breakdown of adenosine (deamination, known as A-to-I editing that occurs in tRNA and mRNA) or also is generated by the action of 5'-nucleotidase on inosine monophosphate (IMP). Inosine has neuroprotective, cardioprotective, immunomodulatory, anti-tumor and anti-inflammatory effects in different experimental models. Inosine functions are mediated in receptor-dependent or-independent manners. The receptor-mediated function of inosine is thought to be related to adenosine receptor family members including A1, A2A, A2B, and A3 G-protein coupled receptors. It is an agonist for adenosine A1 (A1R) and A2A (A2AR) receptors. Inosine is released from brown adipocytes (BAs) upon stress. Inosine activates purinergic P1 receptors, triggering BA activation and white adipocyte browning. Consequently, inosine increases whole-body energy consumption and alleviates diet-induced obesity in mice. Inosine and other closely related purines might be a novel approach to tackle obesity and associated metabolic disorders by enhancing energy expenditure. Inosine is a potent activator of brown adipose tissue and energy homeostasis.
MDL:
MFCD00066770
Molecular Formula:
C10H12N4O5
Molecular Weight:
268.2
Package Type:
Vial
Product Description:
Inosine, an intermediate in purine metabolism, consists of hypoxanthine and ribose. It is an inert purine nucleoside formed by breakdown of adenosine (deamination, known as A-to-I editing that occurs in tRNA and mRNA) or also is generated by the action of 5'-nucleotidase on inosine monophosphate (IMP). Inosine has neuroprotective, cardioprotective, immunomodulatory, anti-tumor and anti-inflammatory effects in different experimental models. Inosine functions are mediated in receptor-dependent or-independent manners. The receptor-mediated function of inosine is thought to be related to adenosine receptor family members including A1, A2A, A2B, and A3 G-protein coupled receptors. It is an agonist for adenosine A1 (A1R) and A2A (A2AR) receptors. Inosine is released from brown adipocytes (BAs) upon stress. Inosine activates purinergic P1 receptors, triggering BA activation and white adipocyte browning. Consequently, inosine increases whole-body energy consumption and alleviates diet-induced obesity in mice. Inosine and other closely related purines might be a novel approach to tackle obesity and associated metabolic disorders by enhancing energy expenditure. Inosine is a potent activator of brown adipose tissue and energy homeostasis.
Purity:
>98% (NMR)
SMILES:
O[C@H]([C@@H](CO)O1)[C@@H](O)[C@@H]1N2C=NC3=C2NC=NC3=O
Solubility Chemicals:
Soluble in water (10mg/ml) or DMSO (10mg/ml).
Source / Host:
Synthetic.
Transportation:
Non-hazardous
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 1 year after receipt when stored at +20°C.
References
The adenosine metabolite inosine is a functional agonist of the adenosine A2A receptor with a unique signaling bias: A.A. Welihinda, et al.; Cell Signal. 28, 552 (2016) | Adenosine-to-inosine RNA editing in neurological development and disease: Y. Yang, et al.; RNA Biol. 18, 999 (2021) (Review) | Inosine in Neurodegenerative Diseases: From the Bench to the Bedside: M.S. Basile, et al.; Molecules 27, 4644 (2022) (Review) | Inosine: A bioactive metabolite with multimodal actions in human diseases: I.S. Kim, et al.; Front. Pharmacol. 13, 1043970 (2022) (Review) | Apoptotic brown adipocytes enhance energy expenditure via extracellular inosine: B. Niemann, et al.; Nature 609, 361 (2022) | Inosine, gut microbiota, and cancer immunometabolism: E. Samami, et al.; Am. J. Physiol. Endocrinol. Metab. 324, E1 (2023) (Review) | Inosine: novel activator of brown adipose tissue and energy homeostasis: A. Pfeifer, et al.; Trends Cell Biol. (epub ahead of print) (2023) (Review)